Claim:

1. Compositions and formulations made of polybasic drugs for reducing multi organ toxicities in mammals, by forming supramolecular cationic complex without chemical cross linking, wherein such complexes comprise of:

(a) a polybasic/ cationic drug selected from a group of aminoglycoside or polymyxins antibiotics;
(b) a cationic compound selected from amino acids wherein the said amino acid is selected from l-arginine, l-lysine, histidine; and
(c) a macromolecule for scaffold base;

wherein the said macromolecule is selected from a group of natural polysaccharide such as dextran,

wherein the said macromolecule is a low molecular weight dextran without chemical modification;

wherein the said complex is formed by cationic electrostatic interactions in specified charge molecular weight relationship;

wherein the ratio of said cationic drug : cationic amino acid: low molecular weight dextran is 1:0.1: 0.1 to 1: 3: 1.

2. Composition of claim 1, wherein the said cationic amino acid is L arginine.

3. Composition of claim 1, wherein the said low molecular weight dextran is dextran 40KDa.

4. Compositions of claims 1 - 3 and formulations made thereof, wherein the said supra molecular cationic complex is formed due to physical connections involving electrostatic interactions, without any conjugation, covalent bond or micelle formulation;

wherein the ratio of said drug to said macromolecule is 1: 0.1 to 1:1;

wherein the ratio of said arginine to said drug is between 0.1:1 to 3:1;

wherein the said supramolecular cationic complex maintains homeostasis when administered parenterally to mammals to reduce multi organ toxicity.

5. Composition of claims 1 - 3 , wherein the said cationic drug is polymyxin B or a pharmaceutical salt thereof which is electrostatically combined with cationic amino acid L arginine along with low molecular weight dextran D40 providing scaffold for physical entrapment;
wherein the ratio of said drug: cationic amino acid: dextran is 1:1.4: 0.2 to 1:2.5: 0.5.

6. Composition of claims 1 - 3, wherein the said cationic drug is polymyxin E or a pharmaceutical salt thereof which is electrostatically combined with cationic amino acid L arginine along with low molecular weight dextran D40 providing scaffold for physical entrapment;
wherein the ratio of said drug: cationic amino acid: dextran is 1: 0.5:0.1 to 1:2:0.25.

7. Composition of claims 1 - 3, wherein the said cationic drug is amikacin or a pharmaceutical salt thereof which is electrostatically combined with cationic amino acid L arginine along with low molecular weight dextran D40 providing scaffold for physical entrapment;
wherein the ratio of said drug: cationic amino acid: dextran is 1: 0.2:0.3 to 1:0.5:0.75.

8. Composition of claims 1 - 3, wherein the said cationic drug is apramycin or a pharmaceutical salt thereof which is electrostatically combined with cationic amino acid L arginine along with low molecular weight dextran D40 providing scaffold for physical entrapment;
wherein the ratio of said drug: cationic amino acid: dextran is 1: 0.1:0.2 to 1:0.5:0.75.

9. Composition of claims 1 - 3, wherein the said supramolecular complex is formed by altering pH of arginine with simultaneous complex formation;
wherein the ratio of said cationic amino acid to said macromolecule in supramolecular cationic complex formation of aminoglycoside polybasic drugs is between 0.25:1 to 1:1.

10. Composition of claims 1 - 3, wherein the said supramolecular complex is formed by cation-π interaction;
wherein the ratio of cationic amino acid to macromolecule in supramolecular cationic complex formation of polymyxin polybasic drugs is between 7.5:1 to 2.5:1.